Plasma lipoproteins were investigated during the active clinical phase of experimental allergic encephalomyelitis (EAE), a demyelinating disease of the central nervous system. Three groups of Lewis rats were compared: untreated controls, Freund's adjuvant-treated controls (FAC), and rats receiving one injection of myelin in Freund's adjuvant. After onset of clinical symptoms, 12 and 16 days after injection, there were higher concentrations of cholesterol and low and high density lipoproteins (LDL and HDL) in EAE plasma. The increase was due to apoE-containing HDL1 and HDL, according to density, particle size, and apolipoprotein compositions of isolated lipoproteins and immunoblots of whole plasmas after gradient gel electrophoresis. In EAE, the cholesterol-to-apoprotein ratio was increased and the low density lipoprotein distribution profile was shifted toward lower density. The Freund's adjuvant-treated control rats showed some changes qualitatively similar to those of EAE, albeit far smaller in magnitude. Changes in LDL in EAE might be related in part to lowered plasma very low density lipoproteins (VLDL); however, weight loss in control animals did not increase plasma cholesterol or apoE relative to apoA-I. Lesions in the central nervous system and/or activation of macrophages might be causally related to the large increase in plasma apoE. The major changes in apoE-containing lipoproteins are undoubtedly significant for the altered immune function in EAE.
Download full-text PDF |
Source |
---|
Heliyon
January 2025
School of Public Health, The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, 561113, China.
Introduction: Obesity is a known risk factor for dyslipidemia. We aimed to evaluate the association between nine obesity indices and various types of abnormal lipid levels in the young and middle-aged.
Methods: From July to November 2022, we distributed health survey questionnaires to the target population in the hospital and collected their biochemical and anthropometric data.
Mol Neurodegener
January 2025
Department of Neurobiology and Behavior, Charlie Dunlop School of Biological Sciences, University of California, Irvine, CA, 92697-4545, USA.
Background: Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer's Disease (AD). However, it remains unclear whether and how this variant exerts its protective effects.
View Article and Find Full Text PDFCardiovasc Diabetol
January 2025
Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave, Tehran, 1995614331, Iran.
Background: Atherogenic index of plasma (AIP), a novel logarithmic index that combines fasting triglyceride and high-density lipoprotein cholesterol concentrations, is associated with the burden of atherosclerosis. This study aimed to evaluate the relationship between AIP and coronary artery disease (CAD) risk, severity, and prognosis in populations with and without established CAD.
Methods: PubMed, Embase, and Web of Science were systematically searched from the inception of each database to August 13, 2024.
Lipids Health Dis
January 2025
Department of Medical Biosciences, Clinical Chemistry, Umeå University, Building 6M 2:Nd Floor, 901 85, Umeå, Sweden.
Background: The ABO blood group system has shown an association with cardiovascular disease. The susceptibility to CVD is proposed to be partly mediated by dyslipidaemia in non-O individuals. Previous studies are scarce for the RhD blood group, but we recently showed that RhD - young individuals are associated with subclinical atherosclerosis.
View Article and Find Full Text PDFJ Clin Lipidol
December 2024
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Centre of Diagnostic Investigation, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Denmark. Electronic address:
Objective: Beyond glucose-lowering, sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardioprotective effects with unclear mechanisms. We examined changes in an extensive panel of plasma lipids, lipoproteins, and apolipoproteins and whether these changes were independent of weight loss, hemoglobin A1c, and hematocrit in patients treated with empagliflozin versus placebo to better understand the observed cardioprotective effects.
Methods: Post-hoc analyses of two double-blind, placebo-controlled trials, the Empire HF trial including 190 patients with heart failure and reduced ejection fraction and the SIMPLE trial including 90 patients with type 2 diabetes randomized to, respectively, 10 mg and 25 mg empagliflozin daily or placebo for 12 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!